ASH Annual Meeting and Exposition

In a small phase I trial, most patients with classical Hodgkin lymphoma, having previously failed three or more therapies, responded to the immunotherapy nivolumab.

A. Keith Stewart, MBChB, from the Mayo Clinic in Scottsdale, Arizona, discusses findings from the phase III ASPIRE trial that evaluated the novel proteasome inhibitor carfilzomib in combination with lenalidomide and dexamethasone for patients with relapsed multiple myeloma.

Stephan Grupp, MD, PhD, of the Children's Hospital of Philadelphia, discusses the optimal treatment settings for novel CD19-specific CAR-modified T cell therapies in patients with acute lymphoblastic leukemia.

The top research being presented at the 2014 American Society of Hematology Annual Meeting will focus on immunotherapies and novel agents, according to Marcel R.M. van den Brink, MD, PhD.

Marcel R.M. van den Brink, MD, PhD, Head, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, provides an overview of five notable studies being presented at the 2014 American Society of Hematology (ASH) Meeting and Exposition.

Jennifer E. Amengual, MD, discusses the development of novel agents for subtypes of diffuse large b-cell lymphoma.

John C. Byrd, MD, from The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), provides an update on ibrutinib for the treatment of CLL.

Pierluigi Porcu, MD, from The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), discusses early research in CTCL.

Eric Padron, MD, discusses the SRSF2 mutation in patients with MDS and CMML.

Mark Shapiro, MD, PhD, discusses bosutinib as treatment for patients with CML.

Timothy S. Pardee, MD, describes a phase I study of the first-in-class pyruvate dehydrogenase complex inhibitor CPI-613 in patients with advanced hematologic malignancies.

Michael A. Caligiuri, MD, CEO, The James Cancer Hospital Solove Research Institute, director, Comprehensive Cancer Center, Ohio State University, discusses the anti-KIR antibody IPH2101 in myeloma and leukemia.

Jasmine Zain, MD, from the Center for the Lymphoid Malignancies, Columbia University Medical Center, discusses two ongoing trials in T-cell lymphomas.

Jennifer E. Amengual, MD, assistant professor of medicine and developmental therapeutics, member, Center for Lymphoid Malignancies, Columbia University, discusses the potential of the combination of vorinostat and niacinamide as treatment for patients with diffuse large B-cell lymphoma.

C. Ola Landgren, MD, PhD, from the National Cancer Institute, discusses a phase II trial that explored the combination of carfilzomib, lenalidomide, and dexamethasone followed by maintenance lenalidomide in patients with newly diagnosed multiple myeloma.

María-Victoria Mateos, MD, PhD, associate professor, hematology, University Hospital of Salamanca, Salamanca, Spain, discusses the design and results of a phase II trial that she presented at the 2013 American Society of Hematology (ASH) Meeting.

James R. Berenson, MD, discusses a phase I/II study looking at pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed/refractory multiple myeloma. The study was presented at the 2013 ASH Meeting.

Combination treatment with idelalisib plus rituximab was associated with a >70% improvement in OS in patients with high-risk relapsed/refractory CLL.

Almost half of patients with relapsed/refractory AML had complete remissions when treated with quizartinib, which also had a more favorable safety profile as compared with higher doses.

Andre Goy, MD, MS, from the John Theurer Cancer Center, discusses the apparent effectiveness of CD19-targeted CAR-modified T cells as a treatment for patients with various types of lymphoma.

Brentuximab vedotin has demonstrated antitumor activity in the setting of relapsed or refractory DLBCL across a broad range of CD30 expression, including low or undetectable CD30 expression.

Jatin J. Shah, MD, from the University of Texas, MD Anderson Cancer Center, describes his excitement over novel therapeutics in development for patients with multiple myeloma.

Several trials of ibrutinib, an oral BTK inhibitor, either alone or in combination with currently used therapies for patients with chronic lymphocytic leukemia were presented at the 55th Annual Meeting of the American Society of Hematology.

Richard R. Furman, MD, from the New York Weill Cornell Medical Center, discusses the ability to avoid the administration of chemotherapy when using novel agents, such as idelalisib, to treat patients with chronic lymphocytic leukemia.

Imetelstat, a telomerase inhibitor, has demonstrated significant activity in myelofibrosis, including complete responses.

The first-in-class targeted agent filanesib has demonstrated promising activity in patients with relapsed and refractory multiple myeloma.

Adding ofatumumab to chlorambucil in patients with previously untreated chronic lymphocytic leukemia who are considered inappropriate for fludarabine improves clinical outcomes and is tolerable irrespective of patient age or fitness.

Jacob Laubach, MD, MPP, from Dana-Farber Cancer Institute, discusses responses observed following the administration of daratumumab for patients with multiple myeloma.

Ian W. Flinn, MD, PhD, from the Sarah Cannon Research Institute, discusses the preliminary efficacy of IPI-145 in patients with chronic lymphocyic leukemia (CLL).

The BTK inhibitor ibrutinib rapidly reduced serum immunoglobulin M levels and improved hematocrit levels in patients with relapsed or refractory Waldenström's macroglobulinemia, and the responses to ibrutinib were durable.